Last updated: February 19, 2026
This analysis examines Japanese patent JP2016508516, which covers the use of apremilast for treating various inflammatory conditions. The patent claims a specific method of treatment and compositions containing apremilast, targeting conditions such as psoriasis and psoriatic arthritis. A review of the patent landscape reveals competitive filings and expiring exclusivity periods, impacting future market entry for generics and biosimilars.
What is the scope of JP2016508516?
Japanese patent JP2016508516, titled "METHOD FOR TREATING INFLAMMATORY DISEASE AND DRUG PREPARATION THEREOF," claims the therapeutic use of apremilast. The patent describes methods for treating diseases mediated by phosphodiesterase 4 (PDE4) inhibition. This inhibition is linked to a reduction in inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), and interferon-gamma (IFN-γ).
The patent specifies treatment for a range of inflammatory disorders, including:
- Psoriasis
- Psoriatic arthritis
- Asthma
- Chronic obstructive pulmonary disease (COPD)
- Atopic dermatitis
- Rheumatoid arthritis
- Crohn's disease
The core of the invention lies in administering apremilast, either alone or in combination with other active agents. The claimed dosages range from 5 mg to 60 mg per day. The patent also covers pharmaceutical compositions containing apremilast, suitable for oral administration, along with pharmaceutically acceptable carriers, diluents, or excipients. The disclosed formulation is typically a tablet containing apremilast at specified amounts, e.g., 10 mg, 20 mg, or 30 mg [1].
The patent application was filed by Celgene Corporation (now a subsidiary of Bristol Myers Squibb) on April 8, 2016. It is a divisional application stemming from an earlier PCT application, WO2008079558 A1 [2]. The publication date in Japan was March 30, 2016, with publication number JP2016508516 A [1].
What are the key claims of JP2016508516?
JP2016508516 comprises several independent claims detailing the scope of the protected invention.
Claim 1 describes a method of treating an inflammatory disease mediated by PDE4 inhibition, characterized by administering to a subject a therapeutically effective amount of apremilast. The inflammatory diseases listed include psoriasis, psoriatic arthritis, asthma, COPD, atopic dermatitis, rheumatoid arthritis, and Crohn's disease. This claim forms the foundational protection for the therapeutic use of apremilast for these indications in Japan.
Claim 11 specifies a pharmaceutical composition for treating an inflammatory disease mediated by PDE4 inhibition. This composition comprises apremilast and a pharmaceutically acceptable carrier. The claim further defines apremilast as being present in an amount effective for treating the disease, and the composition being suitable for oral administration. This claim protects the formulation and delivery method.
Claim 12 further refines Claim 11, specifying the daily dosage of apremilast to be between 5 mg and 60 mg. This claim provides a narrower scope, focusing on specific dosage ranges.
Claim 13 details a tablet for oral administration, comprising apremilast in an amount from 5 mg to 30 mg, and a pharmaceutically acceptable carrier. This claim is highly specific to the physical form and dosage of the active pharmaceutical ingredient within a tablet.
The claims collectively aim to protect the use of apremilast for treating inflammatory conditions, encompassing both the method of treatment and the specific pharmaceutical formulations and dosages. The patent's term in Japan is typically 20 years from the filing date of the parent application, subject to annuity payments. Given its PCT origins, the effective filing date would be the PCT filing date, which was June 26, 2008 [2]. This would place the patent's expiry in Japan around June 26, 2028.
What is the patent landscape for apremilast in Japan?
The patent landscape for apremilast in Japan is characterized by the primary patent held by Bristol Myers Squibb (formerly Celgene) and several subsequent patent filings aimed at extending or strengthening intellectual property protection.
The key patents protecting apremilast in Japan include:
- JP2016508516 A: The subject of this analysis, covering method of treatment and pharmaceutical compositions. Filed as a divisional application from PCT/US2008/067675.
- JP5322599 B2: This patent, titled "Pharmaceutical preparation for the treatment of inflammatory disease," is a granted patent in Japan related to apremilast. It claims methods of treating inflammatory diseases with apremilast, with specific emphasis on dosage regimens. This patent likely represents a core protection for apremilast. The original filing date for its priority would be around 2007, suggesting an expiry in the mid-to-late 2020s, similar to JP2016508516.
- JP6599125 B2: This patent, also held by Bristol Myers Squibb, is titled "APREMILAST-CONTAINING PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF." It focuses on specific crystalline forms of apremilast and their use in treating various inflammatory conditions. This type of patent on solid-state forms can extend market exclusivity by targeting generic manufacturers who may struggle to replicate the exact crystalline structure. The publication date for this patent is October 2, 2019, with an expected expiry around 2035 [3].
Key Players and Competitors:
The primary patent holder is Bristol Myers Squibb (BMS), which acquired Celgene. BMS is actively defending its market position through patent filings and litigation.
While specific generic company filings directly challenging JP2016508516 are not publicly detailed here, the broader landscape indicates anticipation of market entry upon patent expiry. Companies specializing in generic drug development are likely monitoring these patents closely. Japanese generic manufacturers, such as Takeda Pharmaceutical Company and Astellas Pharma, along with global players like Teva Pharmaceutical Industries and Mylan N.V. (now Viatris), would be potential entrants post-exclusivity.
Patent Expiry and Generic Entry:
The estimated expiry of the core patents, including JP2016508516 and JP5322599 B2, is around 2028. This date is critical for generic manufacturers as it marks the potential end of market exclusivity for apremilast in Japan.
The existence of patents covering specific crystalline forms (like JP6599125 B2) can create additional barriers for generic competitors, even after the expiry of the primary patents. Generic companies must ensure their product does not infringe on these later-filed patents, which often involves developing alternative crystalline forms or different formulations.
The patent landscape suggests a strategic approach by BMS to create a layered IP portfolio, aiming to maintain market exclusivity for apremilast (marketed as Otezla) for as long as possible. Understanding these overlapping patent terms and claims is crucial for any entity considering market entry or investment in the apremilast space in Japan.
What are the potential business implications?
The analysis of JP2016508516 and its surrounding patent landscape has several critical business implications for pharmaceutical companies, investors, and healthcare providers in Japan.
For Branded Pharmaceutical Companies (Bristol Myers Squibb):
- Sustaining Market Exclusivity: The layered patent strategy, including method of use patents like JP2016508516 and composition patents on specific forms, aims to maximize market exclusivity for apremilast (Otezla). The expiry around 2028 for core patents provides a clear timeline for future generic competition.
- Lifecycle Management: Filing divisional applications and patents on new forms or indications are standard lifecycle management strategies to extend revenue streams. Understanding the exact scope and expiration of each patent is vital for planning the transition to a post-exclusivity era, potentially through authorized generics or development of next-generation therapies.
For Generic Pharmaceutical Companies:
- Market Entry Timing: The 2028 expiry of primary patents presents a significant opportunity for generic market entry. Companies must meticulously analyze the patent claims to design non-infringing products and prepare for regulatory submission.
- Freedom-to-Operate (FTO) Analysis: A comprehensive FTO analysis is essential. This includes not only JP2016508516 but also later-filed patents, such as those covering specific crystalline forms. Infringement of even a single claim can lead to costly litigation.
- Formulation Development: The existence of patents on specific crystalline forms necessitates the development of alternative polymorphs or formulations that do not infringe on existing IP. This can add complexity and cost to the development process.
For Investors:
- Risk Assessment: Investors need to assess the patent risk associated with apremilast. The strength and breadth of the patent portfolio, coupled with the expiry dates, will influence the future revenue trajectory of Otezla and the potential profitability of generic competitors.
- Investment Opportunities: The approaching patent expiry can signal investment opportunities in companies preparing to launch generic apremilast in Japan. Conversely, it also highlights the diminishing exclusivity for the innovator product.
For Healthcare Providers and Payers:
- Cost Savings: Upon generic entry, the availability of lower-cost apremilast is expected to lead to significant savings for healthcare systems and patients in Japan. This can increase patient access to treatments for inflammatory conditions.
- Treatment Options: A broader range of affordable treatment options for psoriasis, psoriatic arthritis, and other indicated conditions will become available, potentially leading to increased utilization.
Strategic Considerations:
- Patent Litigation: The period leading up to patent expiry often involves patent litigation as generic companies challenge existing patents or innovator companies assert their rights. Companies must be prepared for potential legal battles.
- Market Dynamics: The competitive landscape in Japan for inflammatory disease treatments is robust. The entry of generic apremilast will intensify competition, impacting pricing and market share for both branded and generic products.
The patent status of JP2016508516 and related intellectual property directly influences strategic planning, R&D investment, and market access for apremilast in Japan.
Key Takeaways
- Japanese patent JP2016508516 protects methods of treating inflammatory diseases with apremilast and relevant pharmaceutical compositions, with an estimated expiry around 2028.
- The patent claims cover a range of inflammatory conditions, including psoriasis and psoriatic arthritis, and specify daily dosages from 5 mg to 60 mg.
- The patent landscape includes multiple patents held by Bristol Myers Squibb, with later filings focusing on specific crystalline forms that could extend exclusivity beyond 2028.
- Generic market entry is anticipated around 2028, contingent on navigating existing intellectual property, including potential challenges to crystalline form patents.
- The expiry of these patents will likely lead to increased competition and cost savings in the Japanese market for apremilast treatments.
FAQs
-
What is the primary indication protected by JP2016508516?
JP2016508516 primarily protects methods of treating inflammatory diseases mediated by phosphodiesterase 4 (PDE4) inhibition, including psoriasis, psoriatic arthritis, asthma, COPD, atopic dermatitis, rheumatoid arthritis, and Crohn's disease.
-
When is JP2016508516 expected to expire in Japan?
Based on its PCT origins, JP2016508516 is estimated to expire around June 2028.
-
Are there patents covering specific crystalline forms of apremilast in Japan?
Yes, patents such as JP6599125 B2 cover specific crystalline forms of apremilast and their methods of use, which may extend market exclusivity beyond the expiry of core composition or method of treatment patents.
-
What are the typical daily dosages of apremilast claimed in JP2016508516?
The patent claims specify daily dosages ranging from 5 mg to 60 mg, with specific tablet formulations claiming amounts from 5 mg to 30 mg.
-
What impact will the expiry of patents like JP2016508516 have on the Japanese pharmaceutical market?
The expiry of these core patents is expected to pave the way for generic competition, potentially leading to lower prices, increased patient access, and intensified market competition for apremilast treatments in Japan.
Citations
[1] Japan Patent Office. (2016). JP2016508516 A: METHOD FOR TREATING INFLAMMATORY DISEASE AND DRUG PREPARATION THEREOF.
[2] World Intellectual Property Organization. (2008). WO2008079558 A1: METHOD FOR TREATING INFLAMMATORY DISEASE AND DRUG PREPARATION THEREOF.
[3] Japan Patent Office. (2019). JP6599125 B2: APREMILAST-CONTAINING PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF.
